Kostos L - Search Results

1

Modern paradigms for prostate cancer detection and management.

Williams IS, McVey A, Perera S, O'Brien JS, Kostos L, Chen K, Siva S, Azad AA, Murphy DG, Kasivisvanathan V, Lawrentschuk N, Frydenberg M. Williams IS, et al. Among authors: kostos l. Med J Aust. 2022 Oct 17;217(8):424-433. doi: 10.5694/mja2.51722. Epub 2022 Oct 2. Med J Aust. 2022. PMID: 36183329 Free PMC article. Review.

2

Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond.

Gafita A, Marcus C, Kostos L, Schuster DM, Calais J, Hofman MS. Gafita A, et al. Among authors: kostos l. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-17. doi: 10.1200/EDBK_350946. Am Soc Clin Oncol Educ Book. 2022. PMID: 35609224 Free article.

3

Double or Triple Trouble in Metastatic Hormone-sensitive Prostate Cancer?

Kostos L, Murphy DG, Azad AA. Kostos L, et al. Eur Urol Oncol. 2022 Oct;5(5):503-504. doi: 10.1016/j.euo.2022.07.001. Epub 2022 Jul 19. Eur Urol Oncol. 2022. PMID: 35868978 No abstract available.

4

Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer.

Chen K, Kostos L, Azad AA. Chen K, et al. Among authors: kostos l. World J Urol. 2023 Aug;41(8):2021-2031. doi: 10.1007/s00345-022-04135-8. Epub 2022 Aug 27. World J Urol. 2023. PMID: 36029329 Free PMC article.

5

Treatment options for metastatic hormone-sensitive prostate cancer.

Kostos L, Murphy DG. Kostos L, et al. Lancet Oncol. 2022 Oct;23(10):1234-1235. doi: 10.1016/S1470-2045(22)00520-4. Epub 2022 Sep 5. Lancet Oncol. 2022. PMID: 36075259 No abstract available.

6

Systemic therapy in metastatic hormone-sensitive prostate cancer.

McDonald J, O'Brien J, Kostos L, Lawrentschuk N, Azad AA, Murphy D, Chen K. McDonald J, et al. Among authors: kostos l. Curr Opin Support Palliat Care. 2022 Dec 1;16(4):234-239. doi: 10.1097/SPC.0000000000000622. Epub 2022 Oct 13. Curr Opin Support Palliat Care. 2022. PMID: 36239736 Review.

7

KIT as a therapeutic target in neuroendocrine prostate cancer.

Azad AA, Kostos L, Agarwal N. Azad AA, et al. Among authors: kostos l. Cancer Cell. 2022 Nov 14;40(11):1266-1268. doi: 10.1016/j.ccell.2022.10.010. Epub 2022 Nov 3. Cancer Cell. 2022. PMID: 36332623 Free article.

8

AlphaBet: Combination of Radium-223 and [¹⁷ ⁷Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol).

Kostos L, Buteau JP, Yeung T, Iulio JD, Xie J, Cardin A, Chin KY, Emmerson B, Owen KL, Parker BS, Fettke H, Furic L, Azad AA, Hofman MS. Kostos L, et al. Front Med (Lausanne). 2022 Nov 18;9:1059122. doi: 10.3389/fmed.2022.1059122. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36465905 Free PMC article.

9

Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer.

Kostos L, Buteau JP, Hofman MS, Azad AA. Kostos L, et al. Ther Adv Med Oncol. 2023 Jun 6;15:17588359231179309. doi: 10.1177/17588359231179309. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37323184 Free PMC article. Review.

10

Role of FDG PET/CT in Management of Patients with Prostate Cancer.

Sutherland DEK, Azad AA, Murphy DG, Eapen RS, Kostos L, Hofman MS. Sutherland DEK, et al. Among authors: kostos l. Semin Nucl Med. 2024 Jan;54(1):4-13. doi: 10.1053/j.semnuclmed.2023.06.005. Epub 2023 Jul 1. Semin Nucl Med. 2024. PMID: 37400321 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters